Microbiome Therapeutics Market

Microbiome Therapeutics Market Outlook (2022-2032)

The microbiome therapeutics market size is estimated at US$ 112.20 Million in 2022 and is anticipated to grow at a CAGR of 32% from 2022 to 2032. The microbiome therapeutics market size is anticipated to reach US$ 1801.91 Million in 2032.

The market is expanding as a result of factors including the rise in strategic partnerships for R&D, product development, and portfolio expansion in the field of microbiome therapeutics. The market for microbiome therapeutics was severely harmed by the COVID-19 pandemic. Globally, clinical trial research has been severely disrupted. The demand for microbiome therapeutics is rising as target diseases are becoming more prevalent.

The development of microbiome research is anticipated to aid in the search for more effective cures for infections and other diseases, improving the results of medical treatment. Companies are bringing down the cost of their goods, increasing access to cutting-edge healthcare for a larger portion of the population, and some countries' governing bodies are changing their strategies to support the adoption of microbiome-based treatments. Market vendors now have profitable growth opportunities to increase their market share.

The high cost of microbiome therapeutics and strict regulatory guidelines resulting from the product's complexity are the two main factors limiting the market growth. The overall cost of the product is increased by high development, production, and regulatory costs, which have an impact on treatment costs.

Report Attributes	Details
Microbiome Therapeutics Market Size (2022)	US$ 112.20 Million
Projected Microbiome Therapeutics Market Value (2033)	US$ 1801.91 Million
Global Microbiome Therapeutics Market Growth Rate (2022-2032)	32%
North America Microbiome Therapeutics Market Share 2022-2032)	74%
Clostridium difficileinfection Microbiome Therapeutics Market Share	33%
Key Companies Profiled	OpenBiome Seres Therapeutics Inc. 4D Pharma plc. Locus Biosciences, Inc. Enterome SA Finch Therapeutics Group, Inc. Intralytix, Inc. Microbiotica Second Genome Rebiotix Inc. Vedanta Bioscience, Inc.

Improved Microbiome Sequencing Capabilities are Likely to Boost the Microbiome Therapeutics Market

The main factor anticipated to fuel the growth of the global microbiome therapeutics market is the results of the Human Microbiome Project and other large-scale studies of human bacterial symbioses, which have attracted enormous attention from applied biomedical research organizations. When compared to the Human Microbiome Project (HMP), which identified 60 million genes, 600 microbial reference genomes, and 700 metagenomes, the MetaHIT catalog contains 3.3 million non-redundant human microbiome genes in nearly every set of genes for the human gut microbiome.

The application of therapeutics to the study of the microbiome is made possible by all of this data. Improved microbiome sequencing capabilities are another important factor anticipated to accelerate the growth of the global market for microbiome therapeutics. As a result, it is anticipated that basic research in microbiome sequencing is anticipated to advance and further reveal the diversity of the microbiome, allowing for the development of novel or enhanced microbiome therapeutics.

R&D Initiatives Have Accelerated

R&D efforts started to pick up again as a result of the easing of government restrictions brought on by the epidemic and the introduction of virtual clinical trials. The growing relationship between Big Pharma and microbiome therapies A recent wave of partnerships in this field included Big Pharma as a participant. Big Pharma became more cautious following a number of high-profile failures in clinical trials.

As a result of the decline in the number of significant microbes, dangerous infectious diseases and organisms such as Clostridium difficile and ulcerative colitis have become more prevalent. This has boosted the microbiome therapeutics market trends along with the microbiome therapeutics market adoption trends.

Increasing Production Expenses and Regulatory Burdens are Hurdles

The need for final products with high safety standards that are of clinical grade and that have undergone extensive polishing has led to the adoption of extremely sophisticated methods. The companies in the microbiome industry are anticipated to need to make significant investments in the initial set of production units for such cutting-edge technological methods.

The strict regulatory requirements for sanctioning any new development related to the biopharmaceutical sector have been the main obstacle to the quick development of microbiome therapeutics for various targeted diseases. The development of the global market for microbiome therapeutics is constrained by the incomplete understanding of microbiomes and the testing and approval of therapeutics based on human microbiomes.

Analysis of Segmentation

Which Market Application Segment Is Gaining A Foothold?

The application segment for C. difficile infection is anticipated to contribute the highest share of 33% by 2032. This high microbiome therapeutics market share is thought to be the result of more and earlier launches of C. difficile microbiome therapeutics. The growing use of fecal microbiota transplants (FMT) in the management of C is responsible for the expansion of the microbiome therapeutics market segment.

GI disorders (Crohn's disease, inflammatory bowel diseases, ulcerative colitis), prevention of preterm birth, immuno-oncology, and rare metabolic disorders like phenylketonuria, urea cycle disorders, lactose intolerance, glioblastoma, etc., are some of the other application for which active microbiome therapeutics clinical trials are ongoing.

Due to increased attention being paid to changes in gut microbial composition in Crohn's disease patients, the Crohn's disease application segment of the microbiome therapeutics market is predicted to grow profitably over the course of the forecast period. For instance, according to the Microbiome Journal in 2020, fecal microbiota transplantation can be used to keep patients with Crohn's disease in remission.

Which Market Type Segment is Making Headway?

In the forecast period, faecal microbiota therapy (FMT) held a sizable share of the microbiome therapeutics market. The widespread use of the segment in the management of C. difficile infection is credited with its dominance. Additionally, it is anticipated that the microbiome therapeutics market introduction of capsules and increased R&D concentrating on developments to discover additional therapeutic applications of FMT are anticipated to fuel the microbiome therapeutics market growth.

Due to a strong pipeline and the creation of cutting-edge and novel medications, microbiome drugs are predicted to grow at the fastest rate over the forecast period. Most drugs are still in the early stages of development.

Country Insights

What Should be Expected From The North American Market For Microbiome Therapeutics?

By having the largest microbiome therapeutics market share of 74% for the forecast period, North America dominated the microbiome therapeutics market. The region's dominance is primarily attributed to its well-established research facilities for the creation of novel microbiome therapeutics and its growing target population.

United States

In the global market for microbiome therapeutics, the United States is anticipated to hold the largest market share, exceeding 44%. The United States market for microbiome therapeutics is anticipated to grow as a result of new medications' early release and quick uptake.

In addition, the prevalence of initiatives like the Canadian Microbiome Initiative (CMI) in Canada encourages interaction between partners and stakeholders. Because of this, research can now be concentrated on the creation of microbiome therapeutics.

What are the Microbiome Therapeutics Market Possibilities in Europe?

During the forecast period, Europe is anticipated to show significant growth. In Europe, Germany is a developing market for microbiome therapeutics. Even though microbiome therapeutics are expensive, favorable reimbursement policies are anticipated to make treatment uptake easier in the coming years. Startups are also receiving funding for microbiome-based product development and research.

What Market Opportunities Exist For Microbiome Therapeutics in Japan?

Through the forecast period, Japan is expected to take the lead in the adoption of microbiome therapeutics in the Asia Pacific region. Researchers from Japan are trying to create new products that are anticipated to replicate the beneficial aspects of their microbiota by using the findings of studies on the country's centenarians.

The collaboration aims to overcome some of the biggest technological barriers to furthering stem cell research. The US$ 2.3 million funds were given to Cykinso (Tokyo), who used them to create and market a test kit for intestinal flora called Mykinso. The company intends to use the money for business development activities, which is anticipated to involve creating a system for providing nutritional advice using the information obtained from the intestinal flora tests.

Therefore, it is likely that government investments and initiatives are anticipated to spur microbiome therapeutics market growth during the forecast period.

Comparative View of Adjacent Microbiome Therapeutics Market

Microbiome Therapeutics Market :

Attributes	Microbiome Therapeutics Market
CAGR (2022-2032)	32%
Market Value (2027)	USD 449.64 Million
Growth Factor	The microbiome therapeutics market is expanding as a result of factors including the rise in strategic partnerships for R&D, product development, and portfolio expansion in the field of microbiome therapeutics.
Opportunity	The demand for microbiome therapeutics is rising as target diseases are becoming more prevalent.
Key Trends	These developments are currently in the clinical stage, and it is anticipated that they will soon have a favourable effect on the expansion of the global microbiome therapeutics market.

Skin Microbiome Modulators Market :

Attributes	Skin Microbiome Modulators Market
CAGR (2022-2032)	16%
Market Value (2027)	USD 1773.95 Million
Growth Factor	A Growing Focus on the Health Benefits of the Microbiome
Opportunity	Next-Generation Probiotics Investment for Probiotic Drug Enhancement
Key Trends	More established cosmetic companies are entering the market for skin microbiome regulators.

Neurostimulation Devices Market :

Attributes	Neurostimulation Devices Market
CAGR (2022-2032)	12.8%
Market Value (2027)	USD 9.27 Billion
Growth Factor	The demand for neurostimulation devices is anticipated to increase in the near future due to the rising incidence of neurological diseases.
Opportunity	Implanting a neurostimulation device is a minimally invasive procedure, and the market is anticipated to see new growth opportunities as a result of the growing demand for such surgeries due to shorter hospital stays and quicker recovery.
Key Trends	In order to develop cutting-edge products and technologies, like implantable neurostimulation devices, manufacturers are spending more on research and development (R&D).

Competitive Landscape

The majority of microbiome therapeutics market participants in the microbiome therapeutics space collaborate and partner with well-known pharmaceutical companies and academic institutions. Small start-up and clinical-stage microbiome companies are utilizing venture capital to introduce novel therapeutics based on the microbiome to the global microbiome therapeutics market.

Despite a decline in overall venture capital investments, the microbiome sector saw high VC investments in 2016, raising roughly US$ 336 million. Another significant trend in the market for global microbiome therapeutics is partnerships and research collaborations.

Recent Development :

Date	Company Name	Strategy	Details
January 2022	Hudson Institute and BiomeBank	Agreement	An agreement for a 4-year partnership between Hudson Institute and BiomeBank and BiomeBank for the development and discovery of microbial therapies was signed in January 2022.
February 2022	AOBiome Therapeutics	Research	AOBiome Therapeutics, a clinical-stage biotech company working to develop topical biologic treatments for conditions characterised by systemic inflammation, reported encouraging pivotal Phase 2b results from its trial evaluating B244, the product's topical and intranasal formulation, in pruritus (itch) and the onset of atopic dermatitis in February 2022. (eczema).
2020	4D Pharma	Merger	2020 is anticipated to mark 4D Pharma's transition to NASDAQ public company status after it merged with Longevity Acquisition Corporation. The agreement with Longevity is anticipated to enable support for and advancement of the Live Biotherapeutic created by 4D Pharma. The FDA classifies biological products containing a live organism that are used in the diagnosis, treatment, or prevention of disease as live biotherapeutics.
Early 2022	Nahdi Medical Co. and OptiBiotix Health Plc.	Agreement	An exclusive sales and distribution agreement between Nahdi Medical Co. and OptiBiotix Health Plc. was signed in 2022 and is anticipated to go into effect in 2023. As part of a new agreement with Nahdi, the company's GoFigure and SlimBiome Medical weight management solutions is anticipated to be available in the Kingdom of Saudi Arabia starting in early 2022. This is anticipated to help in the fight against the obesity pandemic.
July 2021	Biocodex Microbiota Foundation	Proposal	The Biocodex Microbiota Foundation published a request for proposals in July 2021 for microbiome research grants totaling more than USD 26,000 in Canada. These grants are anticipated to stimulate new market developments.
December 2021	Kaleido Biosciences and Janssen	Partnership	Kaleido Biosciences and Janssen announced a partnership in December 2021 to explore the potential of microbiome metabolic therapies for the treatment of immune, atopic, and metabolic conditions that first appear in childhood.

Key Segments of Microbiome Therapeutics Industry Research

• By Type :

  • FMT
  • Microbiome Drugs

• By Application :

  • C. difficile
  • Crohn's Disease
  • Inflammatory Bowel Disease
  • Diabetes